UK puberty blockers clinical trial paused over age limit concerns

In Brief

UK trial on puberty blockers paused after regulator advises raising minimum participant age to 14.

Key Facts

• A UK clinical trial investigating puberty blockers for children has been paused.
• The Medicines and Healthcare products Regulatory Agency (MHRA) raised concerns about the trial's minimum participant age.
• MHRA suggested the minimum age for participants should be raised to 14 years old.
• The MHRA cited 'unquantified risk' of long-term biological harms as a reason for pausing the trial.
• Discussions between MHRA and the trial sponsor, King's College London, are scheduled to address these concerns.

What Happened

The UK clinical trial studying puberty blockers for children has been paused following concerns from the Medicines and Healthcare products Regulatory Agency (MHRA). The regulator advised that the trial should have a minimum participant age of 14 due to potential long-term biological risks. King's College London, the trial sponsor, will engage in discussions with MHRA to address these issues.

Why It Matters

The pause highlights regulatory scrutiny over the safety and ethical considerations of puberty blocker treatments in minors. Raising the minimum age could affect recruitment and study outcomes, potentially delaying research into treatment options for children experiencing gender dysphoria. The outcome of discussions may influence future clinical trial protocols and guidelines.